Literature DB >> 9593078

Direct effects of statins on the vascular wall.

A Corsini1, F Pazzucconi, L Arnaboldi, P Pfister, R Fumagalli, R Paoletti, C R Sirtori.   

Abstract

The beneficial effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) on coronary events have generally been attributed to their hypocholesterolemic properties. Mevalonate and other intermediates of cholesterol synthesis (isoprenoids) are necessary for cell proliferation and other important cell functions; thus effects other than cholesterol reduction may help to explain the antiatherosclerotic properties of statins. Recently we provided in vitro and in vivo evidence of decreased smooth-muscle cell (SMC) proliferation and migration by fluvastatin and simvastatin, but not by pravastatin, independent of plasma cholesterol reduction. The ability of fluvastatin to interfere with arterial SMC proliferation at therapeutic concentrations (0.1-1 microM) prompted us to investigate the pharmacologic activity of sera from 10 patients treated with fluvastatin, 40 mg once daily, on the proliferation of cultured human arterial myocytes. Pravastatin, 40 mg once daily, displays a lipid-lowering activity similar to that of fluvastatin without affecting SMC proliferation and was investigated as a control for assessing this non-lipid-related effect of fluvastatin. Fluvastatin and pravastatin, given for 6 days to patients with type IIa hypercholesterolemia, resulted in a similar decrease in low-density-lipoprotein (LDL) cholesterol. However, the addition of 15% whole-blood sera from patients treated with fluvastatin to the culture medium resulted in a 43% inhibition of cholesterol synthesis in SMCs (p < 0.01) that mirrored the pharmacokinetic profile of fluvastatin. When SMC proliferation was investigated, a significant inhibition of cell growth (-30%; p < 0.01) was detected with sera obtained 6 h after the last dose. No effect on SMC proliferation or cholesterol biosynthesis was observed when sera from patients treated with pravastatin were evaluated. These results suggest that statins exert a direct antiproliferative effect on the arterial wall, beyond their effects on plasma lipids, which could prevent significant cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593078     DOI: 10.1097/00005344-199805000-00017

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  13 in total

Review 1.  Antiinflammatory and immunomodulatory properties of statins.

Authors:  Ora Shovman; Yair Levy; Boris Gilburd; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers.

Authors:  S Efrati; M Averbukh; V Dishy; M Faygenzo; L Friedensohn; A Golik
Journal:  Eur J Clin Pharmacol       Date:  2007-01-03       Impact factor: 2.953

3.  The role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in modern rheumatology.

Authors:  Przemyslaw Kotyla
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-10       Impact factor: 5.346

Review 4.  Risks and benefits of continued aggressive statin therapy.

Authors:  Antonio M Gotto
Journal:  Clin Cardiol       Date:  2003-04       Impact factor: 2.882

5.  Effects of immunomodulatory drugs on plasma inflammatory markers in a rabbit model of atherosclerosis.

Authors:  Maha E Houssen; Mona M Haron; Sheren S Metwally; Tarek M Ibrahim
Journal:  J Physiol Biochem       Date:  2010-10-20       Impact factor: 4.158

Review 6.  Fluvastatin: clinical and safety profile.

Authors:  Alberto Corsini; Terry A Jacobson; Christie M Ballantyne
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Simvastatin suppresses the differentiation of C2C12 myoblast cells via a Rac pathway.

Authors:  Tomomi T Baba; Takayuki K Nemoto; Toshihiro Miyazaki; Shinichiro Oida
Journal:  J Muscle Res Cell Motil       Date:  2008-09-16       Impact factor: 2.698

Review 8.  Secondary prevention of atherothrombotic events after ischemic stroke.

Authors:  Harold P Adams
Journal:  Mayo Clin Proc       Date:  2009       Impact factor: 7.616

9.  Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus.

Authors:  Gladys Castaño; Lilia Fernández; Rosa Mas; José Illnait; Meylin Mesa; J C Fernández
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

10.  Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects.

Authors:  Hisako Omori; Hirotaka Nagashima; Yukio Tsurumi; Atsushi Takagi; Naoko Ishizuka; Nobuhisa Hagiwara; Masatoshi Kawana; Hiroshi Kasanuki
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.